Trastuzumab and Pertuzumab in HER2-Positive Metastatic Breast Cancer in West Africa: A Case from Côte d'Ivoire

BITTI ADDE ODO; KOUAME KONAN YVON KOUASSI; YENAHABAN LAZARE TOURE; AMOUGOU FELIX M'BARGA; FEMI PEREZ ODIDI; PETIORI GNINGAYOU LAURENCE TOURE SPOUSE KAMARA; MOHAMED KASSIR AGNIDE MADIOU; N'GUESSAN MANLAN PROSPER MEBIALA; AUDREY FLEUR SESSEGNON; AKISSI MARIE BARBARA YVONE NOGBOU; MOCTAR TOURE; INNOCENT ADOUBI

Issue is not currently published. This is the issue preview only

BITTI ADDE ODO ⁽¹⁾, KOUAME KONAN YVON KOUASSI ⁽²⁾, YENAHABAN LAZARE TOURE ⁽³⁾, AMOUGOU FELIX M'BARGA ⁽⁴⁾, FEMI PEREZ ODIDI ⁽⁵⁾, PETIORI GNINGAYOU LAURENCE TOURE SPOUSE KAMARA ⁽⁶⁾, MOHAMED KASSIR AGNIDE MADIOU ⁽⁷⁾, N'GUESSAN MANLAN PROSPER MEBIALA ⁽⁸⁾, AUDREY FLEUR SESSEGNON ⁽⁹⁾, AKISSI MARIE BARBARA YVONE NOGBOU ⁽¹⁰⁾, MOCTAR TOURE ⁽¹¹⁾, INNOCENT ADOUBI ⁽¹²⁾

(1) CHU DE TREICHVILLE/ UNIVERSITE FELIX HOUPHOUET BOIGNY FACULTE DE MEDECINE, Côte d'Ivoire,

(2) UNIVERSITY OF FELIX HOUPHOUET BOIGNY ABIDJAN , Côte d'Ivoire,

(3) ALASSANE OUATTARA UNIVERSITY , Côte d'Ivoire,

(4) UNIVERSITY OF FELIX HOUPHOUET BOIGNY ABIDJAN , Côte d'Ivoire,

(5) UNIVERSITY OF FELIX HOUPHOUET BOIGNY ABIDJAN , Côte d'Ivoire,

(6) UNIVERSITY OF FELIX HOUPHOUET BOIGNY ABIDJAN , Côte d'Ivoire,

(7) UNIVERSITY OF FELIX HOUPHOUET BOIGNY ABIDJAN , Côte d'Ivoire,

(8) UNIVERSITY OF FELIX HOUPHOUET BOIGNY ABIDJAN , Côte d'Ivoire,

(9) UNIVERSITY OF FELIX HOUPHOUET BOIGNY ABIDJAN , Côte d'Ivoire,

(10) UNIVERSITY OF FELIX HOUPHOUET BOIGNY ABIDJAN , Côte d'Ivoire,

(11) UNIVERSITY OF FELIX HOUPHOUET BOIGNY ABIDJAN , Côte d'Ivoire,

(12) UNIVERSITY OF FELIX HOUPHOUET BOIGNY ABIDJAN , Côte d'Ivoire

Issue
Vol. 12 No. 4 (2025): In-Press for Volume 12, Issue 4, November 2025

Keywords:

Metastatic breast cancer - double anti-HER2 blockade - Survival - Abidjan

No galleys available

Abstract

Context: Dual anti-HER2 blockade with Trastuzumab plus Pertuzumab combined with a taxane is the first line of treatment in metastatic HER2-positive breast cancer. However, few data are available on its efficacy and safety in sub-Saharan African populations.

Materials and methods: Retrospective cohort study with analytical aim on patients followed for HER2-positive metastatic breast cancer in the different public hospital structures for cancer management in Abidjan (CHU de Treichville and CNRAO) over a 02 years period from January 1, 2021 to December 31, 2022.

Results: We collected 30 cases. The median age of patients was 47.2 years, with extremes ranging from 35 to 75 years . Common metastatic sites were lung (63.7%), pleura (20%), liver (20%), bone (16.7%) and brain (6.7%). The most frequent adverse events were hematological and digestive. The objective response rate was 60%. Progression-free survival was 15.3 months. Overall survival was not achieved. Factors associated with better progression-free survival were the absence of brain metastases and the administration of double anti-HER2 blockade as first-line therapy.

Conclusion: Double anti-HER2 blockade showed therapeutic activity in terms of objective response, progression-free survival and tolerability.

Full text article

Generated from XML file